Core Viewpoint - A class action lawsuit has been filed against Cerevel Therapeutics Holdings, Inc., Bain Capital Investors, LLC, and Pfizer, Inc. for alleged violations of federal securities laws, particularly concerning misleading statements and undisclosed material facts related to Cerevel's stock offerings and acquisition processes [1][5][6]. Group 1: Legal Actions and Allegations - The class action targets investors who sold or held Cerevel stock during specific periods, claiming damages due to violations of the Securities Exchange Act of 1934 [1][3]. - The complaint alleges that Bain acquired Cerevel shares during a secondary stock offering while possessing nonpublic information about AbbVie's acquisition interest, leading to significant profits for Bain when the acquisition was later disclosed at $45 per share [5][6]. - The January 18, 2024, Proxy statement for the AbbVie acquisition is claimed to have misled investors regarding the sales process and conflicts of interest, suggesting that Bain and Pfizer orchestrated the process to maximize profits at the expense of public shareholders [5][6]. Group 2: Firm Information and Contact - Faruqi & Faruqi, LLP is a national securities law firm with a history of recovering hundreds of millions for investors since its establishment in 1995 [4]. - The firm encourages individuals with information regarding Cerevel's conduct to come forward, including whistleblowers and former employees [8].

Core Viewpoint - Rosen Law Firm is reminding investors who sold or held shares of Cerevel Therapeutics Holdings, Inc. during a specified period about their potential entitlement to compensation through a class action lawsuit [1][2]. Group 1: Class Action Details - The class period for the lawsuit is from October 11, 2023, to August 1, 2024, and includes those who held shares as of January 8, 2024, and those who sold shares around Bain Capital's purchase on October 16, 2023 [1]. - A class action lawsuit has already been filed, and interested parties can join by contacting Rosen Law Firm [3][6]. - The deadline to serve as lead plaintiff is June 3, 2025, which requires a motion to the Court [3]. Group 2: Legal Representation - Rosen Law Firm emphasizes the importance of selecting qualified legal counsel with a successful track record in securities class actions [4]. - The firm has a history of significant settlements, including over $438 million recovered for investors in 2019 alone [4]. Group 3: Case Allegations - The lawsuit alleges that during the class period, Cerevel's controlling shareholders made false and misleading statements related to a secondary stock offering on October 16, 2023 [5]. - The secondary offering was purportedly designed to allow Bain Capital to increase its stake in Cerevel at a discounted price before AbbVie Inc.'s acquisition announcement, which was made just 51 days later at $45 per share, nearly double the offering price [5].

Core Viewpoint - Rosen Law Firm is reminding investors who sold or held shares of Cerevel Therapeutics Holdings, Inc. during a specified period about their potential entitlement to compensation through a class action lawsuit [1][2]. Group 1: Class Action Details - The class period for the lawsuit is from October 11, 2023, to August 1, 2024, and includes those who held shares as of January 8, 2024, and those who sold shares around Bain Capital's purchase on October 16, 2023 [1]. - Investors may join the class action without incurring out-of-pocket fees through a contingency fee arrangement [2]. - A class action lawsuit has already been filed, and interested parties must move to serve as lead plaintiff by June 3, 2025 [3]. Group 2: Case Allegations - The lawsuit alleges that during the class period, Cerevel's controlling shareholders made false and misleading statements related to a secondary stock offering on October 16, 2023, and a proxy statement on January 18, 2024 [5]. - The secondary stock offering was purportedly designed to allow Bain Capital to increase its stake in Cerevel at a discounted price before AbbVie Inc.'s acquisition announcement [5]. - Following the offering, AbbVie announced its acquisition of Cerevel for $45 per share, nearly double the offering price, resulting in Bain Capital receiving over $120 million in windfall profits [5]. Group 3: Rosen Law Firm's Credentials - Rosen Law Firm emphasizes the importance of selecting qualified legal counsel with a successful track record in securities class actions [4]. - The firm has achieved significant settlements in the past, including over $438 million for investors in 2019 and has been ranked highly in securities class action settlements since 2013 [4].

Core Viewpoint - Cerevel Therapeutics Holdings, Inc. is facing a class action lawsuit from investors who purchased securities during the specified class period, alleging material omissions and misconduct related to a secondary stock offering and misleading statements regarding an acquisition by AbbVie [1][3]. Group 1: Class Action Details - The class action lawsuit represents investors who bought securities between October 11, 2023, and August 1, 2024, with a deadline for filing a lead plaintiff motion set for June 3, 2025 [1]. - The lawsuit claims that Cerevel's secondary stock offering on October 16, 2023, was manipulated by controlling shareholders Bain and Pfizer to allow Bain to increase its stake at a discounted price before AbbVie's acquisition announcement [3]. Group 2: Financial Implications - The complaint alleges that the offering price was significantly lower than the acquisition price of $45 per share announced by AbbVie just 51 days later, resulting in a windfall of over $120 million for Bain [3].

Core Viewpoint - Rosen Law Firm is reminding investors who sold or held shares of Cerevel Therapeutics Holdings, Inc. during a specified period about their potential entitlement to compensation through a class action lawsuit [1][2]. Group 1: Class Action Details - The class period for the lawsuit is from October 11, 2023, to August 1, 2024, and includes those who held shares as of January 8, 2024, and those who sold shares around Bain Capital's purchase on October 16, 2023 [1]. - Investors may join the class action without any out-of-pocket fees through a contingency fee arrangement [2]. - A lead plaintiff must be appointed by June 3, 2025, to represent other class members in the litigation [3]. Group 2: Legal Representation - Rosen Law Firm emphasizes the importance of selecting qualified legal counsel with a proven track record in securities class actions [4]. - The firm has achieved significant settlements in the past, including over $438 million for investors in 2019 and has been consistently ranked among the top firms in securities class action settlements [4]. Group 3: Case Allegations - The lawsuit alleges that during the class period, Cerevel's controlling shareholders made false statements related to a secondary stock offering on October 16, 2023, which allowed Bain Capital to acquire shares at a discounted price before AbbVie Inc.'s acquisition announcement [5]. - Following the acquisition announcement, Cerevel's stock was valued at $45 per share, nearly double the offering price, resulting in Bain Capital receiving over $120 million in windfall profits [5].

Core Viewpoint - Rosen Law Firm is reminding investors who sold or held shares of Cerevel Therapeutics Holdings, Inc. during a specified period about their potential entitlement to compensation through a class action lawsuit [1][2]. Group 1: Class Action Details - The class period for the lawsuit is from October 11, 2023, to August 1, 2024, and includes those who held shares as of January 8, 2024, and those who sold shares around Bain Capital's purchase on October 16, 2023 [1]. - Investors can join the class action without any out-of-pocket fees through a contingency fee arrangement [2]. - A lead plaintiff must be appointed by June 3, 2025, to represent other class members in the litigation [3]. Group 2: Case Allegations - The lawsuit alleges that during the class period, Cerevel's controlling shareholders, Bain Capital and Pfizer, made false statements related to a secondary stock offering on October 16, 2023, and a proxy statement on January 18, 2024 [5]. - The secondary stock offering allowed Bain Capital to acquire shares at a discounted price before AbbVie Inc.'s acquisition announcement, which was made just 51 days later at $45 per share, nearly double the offering price [5]. - Bain Capital's discounted purchases from the offering resulted in a windfall of over $120 million when the true details were revealed [5]. Group 3: Rosen Law Firm's Credentials - Rosen Law Firm has a strong track record in securities class actions, having achieved the largest settlement against a Chinese company at the time and being ranked No. 1 for securities class action settlements in 2017 [4]. - The firm has recovered hundreds of millions of dollars for investors, including over $438 million in 2019 alone [4]. - Many attorneys at the firm have received recognition from Lawdragon and Super Lawyers, highlighting their expertise in this area [4].

Core Viewpoint - Rosen Law Firm is reminding investors who sold or held shares of Cerevel Therapeutics Holdings, Inc. during a specified period about their potential entitlement to compensation through a class action lawsuit [1][2]. Group 1: Class Action Details - The class period for the lawsuit is from October 11, 2023, to August 1, 2024, and includes those who held shares as of January 8, 2024, and those who sold shares around Bain Capital's purchase on October 16, 2023 [1]. - A class action lawsuit has already been filed, and interested parties can join by contacting Rosen Law Firm [3][6]. Group 2: Allegations Against Cerevel - The lawsuit alleges that during the class period, Cerevel made false and misleading statements related to its secondary stock offering on October 16, 2023, and its proxy statement on January 18, 2024 [5]. - It is claimed that Bain Capital and Pfizer orchestrated the secondary stock offering to allow Bain to increase its stake at a discounted price before AbbVie Inc.'s acquisition announcement, which was made 51 days later at $45 per share, nearly double the offering price [5]. Group 3: Rosen Law Firm's Credentials - Rosen Law Firm has a strong track record in securities class actions, having achieved significant settlements, including the largest securities class action settlement against a Chinese company at the time [4]. - The firm has been consistently ranked among the top firms for securities class action settlements and has recovered hundreds of millions of dollars for investors [4].

Core Viewpoint - Cerevel Therapeutics Holdings, Inc. is facing a class action lawsuit from investors who purchased securities during the specified class period, alleging material omissions and misconduct related to a secondary stock offering and misleading statements regarding an acquisition by AbbVie [1][3]. Group 1: Class Action Details - The class action lawsuit seeks to recover losses for shareholders allegedly harmed by Cerevel's secondary stock offering on October 16, 2023, and false statements in the January 18, 2024 Proxy Statement regarding AbbVie's acquisition at $45 per share [3]. - The lawsuit claims that the October 2023 offering was orchestrated by Cerevel's controlling shareholders, Bain and Pfizer, to allow Bain to increase its stake at a discounted price before the undisclosed acquisition by AbbVie [3]. - Following the offering, Cerevel announced the acquisition by AbbVie for $45 per share, which was nearly double the offering price, resulting in a windfall of over $120 million for Bain [3]. Group 2: Investor Actions - Investors are encouraged to contact attorney Lesley F. Portnoy to discuss their legal rights and options for pursuing claims to recover losses [2]. - The deadline for investors to file a lead plaintiff motion is June 3, 2025 [1].

Core Viewpoint - A class action lawsuit has been filed against Cerevel Therapeutics Holdings, Inc., Bain Capital Investors, LLC, and Pfizer, Inc. for alleged violations of federal securities laws, particularly concerning misleading statements and undisclosed material facts related to Cerevel's stock offerings and acquisition processes [6][7]. Group 1: Legal Actions and Allegations - The class action targets investors who sold or held shares of Cerevel between October 11, 2023, and August 1, 2024, claiming damages due to violations of the Securities Exchange Act [1]. - The lawsuit alleges that Bain Capital acquired shares during a secondary offering while possessing nonpublic information about AbbVie's interest in acquiring Cerevel, leading to significant profits for Bain when the acquisition was later disclosed at $45 per share [6][7]. - The complaint also claims that Cerevel's proxy statement misled investors regarding the sales process and conflicts of interest, suggesting that Bain and Pfizer orchestrated the offering to maximize profits at the expense of public shareholders [6][7]. Group 2: Investor Information and Actions - Faruqi & Faruqi, LLP is investigating claims against Cerevel and reminds investors of the June 3, 2025, deadline to seek lead plaintiff status in the class action [4]. - Investors are encouraged to contact Faruqi & Faruqi for discussions regarding their legal rights and potential claims related to the lawsuit [1][9]. - The firm has a history of recovering hundreds of millions of dollars for investors since its founding in 1995, indicating its experience in handling such cases [5].

Core Viewpoint - A class action lawsuit has been filed against Cerevel Therapeutics Holdings, Inc. for violations of federal securities laws, impacting investors who sold shares during a specified period, held shares on a record date, or sold shares during a significant transaction involving Bain Capital [1][2][3] Group 1: Lawsuit Details - The lawsuit includes three classes of investors: those who sold shares between October 11, 2023, and August 1, 2024, those who held shares as of January 8, 2024, and those who sold shares around Bain Capital's purchase on October 16, 2023 [1] - The complaint alleges that Cerevel's October 16, 2023, secondary stock offering omitted material facts about AbbVie's interest in acquiring Cerevel, which led to an artificially low stock price [2] - Following the October Offering, Cerevel announced a merger with AbbVie at $45 per share, resulting in significant financial gains for Bain Capital, which acquired shares at a depressed price [3] Group 2: Financial Impact - Bain Capital reportedly received over $120 million from the shares acquired during the October Offering due to the subsequent merger announcement [3] - Investors who suffered losses exceeding $50,000 in Cerevel's securities are encouraged to participate in the lawsuit [4]